Unveiling the Longitudinal Journey: Three-Year Follow-up of Women with MINOCA and INOCA in a Specialized Heart Centre

Emilie T. Théberge MSc[a]†, Elizabeth Burden MD[a]†, Katrina Leung BSc[a], Mahraz Parvand MSc MD[a,b], Natasha Prodan-Bhalla BScN, DNP[a,b,c] Karin H. Humphries DSc[a], Tara L. Sedlak MD MBA FRCPC[a,b,c]*

[a] University of British Columbia, Vancouver, British Columbia, Canada

[b] Vancouver Coastal Health, Vancouver, British Columbia, Canada

[c] BC Women's Hospital, Vancouver, British Columbia, Canada

† Co-first authors

* Corresponding author

Dr. Tara Sedlak

Division of Cardiology, Vancouver General Hospital

9th Floor, 2775 Laurel St.

Vancouver, British Columbia, V5Z 1M9, Canada.

Tel.: 1-604-875-5487, Fax: 604-875-5504

E-mail: Tara.Sedlak@vch.ca

Word count: 5978

Short title: MINOCA/INOCA patient outcomes after 3 years

Abstract

Background: Myocardial infarction with no obstructive coronary arteries (MINOCA) and ischemia with no obstructive coronary arteries (INOCA), are female predominant conditions, with a lack of clinical trials guiding medical management for the common underlying vasomotor etiologies. Long-term outcomes of (M)INOCA patients are also lacking.

Methods: Women diagnosed with MINOCA (n=51) or INOCA (n=112) were prospectively followed for 3 years at the Vancouver Women's Heart Center (WHC). Baseline characteristics, diagnoses, chest pain type, major adverse cardiac events, hospital encounters, medications, and Seattle Angina Questionnaire (SAQ) responses were compared between baseline and 3 years. Chi-squared tests were used to compare categorical variables and students' t-tests for continuous variables.

Results: MINOCA patients had significantly more non-exertional chest pain and diagnoses of vasospasm than INOCA patients, who had more exertional chest pain and diagnoses of coronary microvascular dysfunction. Following baseline, both groups had significant reductions in cardiovascular emergency room visits, with INOCA patients also experiencing fewer cardiovascular hospitalizations. At 3 years, the most commonly prescribed medications were calcium channel blockers, long-acting nitrates, beta blockers and statins, with MINOCA having more acetylsalicylic acid and INOCA more short-acting nitrates and ranolazine prescriptions. Both groups observed significant improvements in SAQ scores, with greater improvements observed in INOCA patients, although patients with depression at baseline or prescribed ranolazine at 3 years had worse SAQ scores at baseline.

Conclusions: Three-year outcomes of (M)INOCA patients indicate that the WHC's comprehensive care model effectively improves diagnostic clarity, reduces hospital encounters, optimizes medication management, and improves self-reported patient well-being.

Introduction

Nonobstructive coronary syndromes, including myocardial infarction with no obstructive coronary arteries (MINOCA) and ischemia with no obstructive coronary arteries (INOCA), present unique challenges in cardiology as a result of their enigmatic nature and clinical implications. Both are characterized by less than 50% stenosis in any major coronary artery, MINOCA in the setting of myocardial infarction (MI) and INOCA with ischemia. MINOCA afflicts up to 6% of individuals experiencing an acute coronary syndrome, moreso if they are women[1,2]. Similarly, two thirds of angiograms for women with suspected cardiac ischemia reveal INOCA, at a prevalence twice that seen in men. Predominant underlying ischemic etiologies of these two syndromes ("(M)INOCA") include coronary vasospasm and coronary microvascular dysfunction (CMD), conditions that are more common in women and are found to have more nontraditional risk factors as compared to those with obstructive coronary artery disease (CAD)[3].

While (M)INOCA were previously considered benign and managed conservatively, these entities have gained attention in recent years due to their association with adverse cardiac outcomes and mortality[4,5]. A 2022 systematic review and meta-analysis assessing sex-related discrepancies in MINOCA outcomes revealed a higher incidence of major adverse cardiac events (MACE) in women as compared to men within 24 months, largely driven by a greater incidence of stroke[6]. This holds true in INOCA patients, with a 2.55-fold higher risk of MACE in women with INOCA compared to women with no CAD within one year following angiographic investigations[7]. Beyond this,

patients with nonobstructive coronary syndromes are burdened with poor physical functioning, recurrent angina, and reduced quality of life[8,9].

At this juncture, there is a lack of randomized controlled trial data to provide guidance on medical treatment strategies in patients with (M)INOCA. As such, prescribing practices are on the basis of observational data and a personalized approach to the underlying etiology. This is supported by the CorMicA trial, which demonstrated that stratified medical therapy based on invasively diagnosed etiology significantly improved treatment satisfaction, angina severity, and quality of life[10].

Women's Heart Centres (WHC) provide specialized and comprehensive care tailored specifically to the unique needs of women[11]. In our previous study, Parvand et al. showcased 1-year prospective data suggesting WHC enrolment resulted in higher diagnostic yield, improved risk-factor management, and reduced angina hospitalization in women presenting with (M)INOCA[12]. Furthermore, due to the heterogeneity of the (M)INOCA patient population, access to a WHC may allow for tailored prescribing practices.

Overall, there remains a paucity of data evaluating the role of specialized WHCs in the longitudinal follow-up of (M)INOCA patients. The aim of this work was to provide more detailed insights into the outcomes, diagnoses, longer-term therapeutic management, and modifiers of patient-reported outcomes for this population after 3-years of follow-up in a WHC.

Methods

Study Design and Population

Female patients with MINOCA or INOCA referred to the Leslie Diamond WHC in Vancouver, Canada, were identified for WHC Registry study enrollment. Consented patients were prospectively followed for 3 years.

Data Collection

Patient data obtained from questionnaires were stored using a REDCap database. Demographic, clinical and female-specific variables were captured from the baseline WHC clinical consult visit notes and/or verbal self-report to the study coordinator and also entered into the REDCap database. Full definitions of each variable are described in the Supplemental Methods. A key exposure variable was a history of clinical depression. Depression was considered present if any of the following 3 criteria were met: 1. Recent or current clinical depression diagnosis indicated in baseline consultation notes; 2. Baseline Patient Health Questionnaire (PHQ-9) questionnaire score of ≥10 points[13]; or 3. Currently taking (an) antidepressant(s). This composite definition was used to account for self-report bias and/or inconsistent diagnostic appraisal possible between health providers[14]. Composite metrics for depression, integrating antidepressant use, questionnaire response and self-report data have been previously shown to improve validity of depression studies[15].

Another parameter of interest was baseline cardiac diagnosis. Referral letters from primary care or specialist physicians were reviewed to quantify the degree to which

undiagnosed chest pain in (M)INOCA patients had been investigated towards a diagnosis of a vasomotor (CMD, coronary vasospasm) or other non-vasomotor etiology. The resulting diagnosis from investigations ordered and/or medications prescribed during attendance at the WHC were identified from physician consult notes. Probable or confirmed CMD and coronary vasospasm were defined using the Coronary Vasomotion Disorder International Study (COVADIS) group definitions[16] and are further described in the Supplemental Methods. Baseline WHC physician consult notes were reviewed for descriptors of chest pain on exertion, chest pain at rest or while sleeping, and/or chest pain during stress or emotional triggers. These terms were explicitly stated as such in the consult notes, and any categorization ambiguities were clarified before categorization.

Medications were quantified at baseline and 3-years. The baseline medications reflect what the patient was taking prior to the WHC appointment. The 3-year medications were identified from the most recent physician consult notes, reflecting changes done in the WHC. For patients with medications data at both baseline and 3-years, changes in medications were analyzed on a per-individual basis.

Study Outcomes

Hospital encounters, defined as emergency room (ER) visits for chest pain, hospitalizations for any cardiovascular cause, and MACE, were quantified within the 3 years prior to the baseline WHC visit and up to 3 years post-baseline. Only electronic health record encounters in British Columbia were accessible. MACE comprised MI, stroke, heart failure, or cardiovascular death. Transient ischemic attacks (TIA) were also

counted but were noted separately as they are known precursors to stroke within 1 year[17]. For MINOCA patients, their first (index) MI was excluded from the pre-baseline hospitalization count.

The Seattle Angina Questionnaire (SAQ)[18] was administered at baseline and 3-years. Four subdomains of the SAQ were assessed: physical limitation, angina frequency, quality of life, and treatment satisfaction. Scores were scaled to a 100-point scale prior to analysis. Scaled scores between 0-24 represent severe angina, 25-74 as moderate angina, are moderate angina, and over 75 as mild to no angina[19]. The minimal clinically important difference (MCID) for the SAQ is 10 points on the 100-point scale[18]. SAQ subdomain scores were further stratified and analyzed by the presence of depression at baseline or prescription of ranolazine by year 3. We hypothesized that patients with depression at baseline would have worse SAQ scores, as depression has been demonstrated to accentuate perceptions of pain[20]. Further, as ranolazine is used as a second- or third-line anti-anginal agent, we hypothesized that patients prescribed this medication would have worse SAQ scores at baseline owing to more challenging to manage angina.

Statistical Analyses

Baseline characteristics are reported as means and standard deviations (SD) for continuous variables and counts and percentages for categorical variables. Comparisons between MINOCA and INOCA groups were conducted using Chi-squared tests or Student's t-test for categorical and continuous variables, respectively. Statistical

significance in the number of ER visits, hospitalizations and MACE events between baseline and year 3 timepoints were calculated using McNemar's test.

Overall SAQ scores by subdomain were compared using Student's t-tests. Two variables were investigated as modifiers of SAQ scores at baseline, at 3 years, and the effect on the difference between baseline and 3 years: 1) Depression status at baseline (yes/no) and 2) ranolazine prescription status at 3 years (yes/no). For each analysis, Students' t-tests were used to compare mean questionnaire scores for each modifier variable. Baseline and year 3 scores within groups were compared using paired Wilcoxon rank sum tests for each subdomain, as data were non-normally distributed. To assess if the depression and ranolazine impacted the change in questionnaire scores over time, differences between baseline and 3-year scores were first calculated for each patient, then the means of each variable, stratified by the presence/absence of each modifier variable, were compared using the Student's t-test. Linear regression models were plotted to display trends.

Results

Baseline Characteristics

There were 163 patients eligible for analysis with complete baseline and 3-year questionnaires, and diagnoses of MINOCA (n=51) or INOCA (n=112). Among demographic, clinical and female-specific variables, there were no significant differences observed between MINOCA and INOCA patients, except for migraines,

which were significantly more prevalent in MINOCA patients (23, 45%) than INOCA patients (28, 25%) (Table 1).

Diagnoses & Presentation Type

Most patients who were referred to the WHC with chest pain did not have a specific etiology diagnosed (131, 80%). A minority (32, 20%) of the referrals requested medical management consultation for chest pain with prior diagnosed CMD (8, 5%), vasospasm (9, 6%) or other diagnoses (15, 9%).

Figure 1 demonstrates pre- versus post-WHC diagnostic changes. Table 2 summarizes the specific etiologies by (M)INOCA groups studied. Most had a final vasomotor diagnosis of either CMD (92, 56%) or vasospasm (42, 26%). The majority of INOCA patients had CMD (85, 76%) followed by vasospasm (18, 16%), and the majority of MINOCA patients had vasospasm (24, 47%) followed by a non-vasomotor etiology (18, 35%). There were significantly more MINOCA patients with vasospasm (47%) or another non-vasomotor etiology (35%) compared to INOCA, with 16% and 4% respectively. In contrast, significantly more INOCA patients had CMD (76%) than MINOCA patients (14%). Among the 22 patients with "other" non-vasomotor diagnoses following WHC assessment, 5 had Takotsubo cardiomyopathy only, 1 had Takotsubo with CMD, 2 had Takotsubo with spontaneous coronary artery dissection (SCAD), 5 had SCAD and CMD, 1 had SCAD and vasospasm, 1 had SCAD only, 4 had myocarditis, 1 had coronary embolism, 1 had both vasospasm and CMD, and 1 had mild plaque with aortic stenosis. If patients were ascertained to have SCAD prior to baseline WHC attendance, they were triaged to a dedicated SCAD clinic at our centre.

Presentation

There were significant differences in the frequency of the types of chest pain observed between MINOCA and INOCA patients, with the majority of both groups displaying multiple types (Table 3, $p<0.001$). MINOCA patients had more presentations of chest pain only at rest (20% versus 4% in INOCA) and INOCA patients had more chest pain only on exertion (36% versus 10% in MINOCA).

Within a subset of patients stratified by vasospasm or CMD etiology instead of (M)INOCA, significantly more patients with CMD had an exertional component to their chest pain (80, 87%) compared to vasospasm (19, 45%) patients (Table 4, $p<0.001$). Conversely, significantly more patients with vasospasm had a component of non-exertional chest pain (28, 67%) compared to patients with CMD (34, 37%). The frequency of stress or emotional trigger-induced chest pain did not vary between groups.

Hospital Encounters and MACEs

Significantly fewer ER visits for chest pain were observed following WHC attendance for both MINOCA (92% to 51%) and INOCA patients (50% to 32%) (Table 5). INOCA patients had significantly fewer hospitalizations for any cardiovascular reason post-WHC (20% to 5%) but not MINOCA patients (4% to 8%).

Low rates of MACE were observed among MINOCA and INOCA patients (Table 6). All MINOCA patients had NSTEMIs. 49 (96%) patients had their index MI event within 3 years prior to the baseline WHC visit. In the 3 years following baseline, among MINOCA

patients, one patient had an MI and subsequent PCI, one (different) patient had a TIA, and no heart failure events or deaths were observed. Among the 2 INOCA patients who had a TIA event post-baseline, one had already had a TIA prior to baseline. The observed death was of unknown cause.

Medications and Therapies

Changes in the number and proportion of patients on various medical therapies are summarized in Figure 2 (Supplemental Table S1). At baseline, in quantifying the 5 most frequently used medications for both MINOCA and INOCA, MINOCA had more angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEi/ARBs) at baseline than INOCA, and INOCA had more antidepressants. Both groups shared similarly high prescriptions of acetylsalicylic acid (ASA), statins, 1,4-dihydropyridine calcium channel blockers (DHP-CCBs) and beta blockers (BBs) at baseline. At 3 years, MINOCA patients had more ASA than INOCA, and INOCA had more short-acting nitrates. Otherwise, both groups shared similarly high prescriptions of DHP-CCBs, long-acting nitrates, BBs, and statins.

Changes in prescriptions between baseline and 3 years are summarized in Figure 3 (Supplemental Table S2). For MINOCA, the greatest increases in medications were long-acting nitrates (13, 28%), short-acting nitrates (9, 19%), BBs (8, 17%) and ASA (7, 15%). ASA, non-ASA antiplatelets and BBs demonstrated the highest rates of discontinuation (6 each, 13%). For INOCA, the greatest increases in medications were long-acting nitrates (41, 38%), DHP-CCBs (29, 27%), short-acting nitrates (27, 25%) and ranolazine (24, 22%). ASA (13, 12%) and short-acting nitrates (8, 7%) were the

most frequently discontinued, followed by long-acting nitrates (7, 6%), BBs and DHP-CCBs (each 6, 6%). Medications that report high rates of both prescription and discontinuation are reflective of different patients being treated.

Questionnaires

Improvements in SAQ subdomain scores were noted in both MINOCA and INOCA groups between baseline and 3 years (Table 7). Among MINOCA patients, significant improvements were observed in all subdomains, except for physical limitations. In contrast, significant improvements were observed across all domains in INOCA patients. When investigating SAQ subdomains based on whether MCID were achieved, a higher relative proportion of INOCA patients were observed to have clinically meaningful improvements across all domains except treatment satisfaction compared to MINOCA patients (Figure 4, Supplemental Table S3).

Patients with depression at baseline had significantly worse SAQ scores compared to patients without depression at baseline (all $p<0.05$), and at 3 years in the physical limitations ($p=0.006$) and angina frequency domains ($p=0.03$) (Figure 5, Supplemental Table S4). Depression at baseline was not found to be a significant modifier for any of the SAQ subdomains ($\Delta p > 0.05$).

Patients on ranolazine at year 3 had significantly worse SAQ scores for all subdomains at baseline, and for the physical limitations and angina frequency subdomains at year 3 (Figure 6, Supplemental Table S5). Ranolazine at year 3 was found to be a significant

modifier for the treatment satisfaction subdomain ($\Delta p=0.02$), but not the other subdomains ($\Delta p > 0.05$).

Discussion

In this work, we sought to address the void of longer-term data describing (M)INOCA patients by presenting 3-year outcomes after attending a Canadian WHC. In summary, over 95% of both groups received a diagnosis, showing improved diagnostic clarity. Hospital encounters, particularly emergency visits, significantly decreased; INOCA patients also experienced fewer cardiovascular hospitalizations. Medication adjustments were notable, with a reduction in non-ASA antiplatelets and a personalized approach for beta blockers. Ranolazine was frequently prescribed for INOCA patients, suggesting a challenging symptom profile in this cohort that often requires second- or third-line anti-anginal agents. Mental health at baseline was an important component towards self-reported angina, as patients with depression had worse baseline SAQ metrics, but demonstrated comparable improvements to those without depression.

While 71.4% of INOCA patients and 60% of MINOCA patients had new or changed diagnoses at 1-year[12], by 3-years of follow-up a diagnosis was achieved in 95.5% of INOCA patients and 96.1% of MINOCA patients. This improvement in diagnostic yield is suggestive of the access to testing and diagnostics through longer follow-up at the WHC including invasive coronary reactivity testing and adenosine cardiac magnetic resonance imaging.

Women with chest pain and nonobstructive coronary syndromes frequently utilize hospital resources[21]. We demonstrated a significant reduction in emergency department presentations following enrolment and follow-up in a WHC. INOCA patients also had significantly reduced cardiovascular hospitalizations, unlike MINOCA patients, who had low baseline rates excluding their index hospitalization.

We acknowledge the low rate of MACE endpoints, which limits our ability to detect significant differences. Amongst the WISE cohort, which followed female patients with predominantly non-obstructive disease, the 10-year risk for MACE was first reported at 6.7% and 12.8% for 10-years of follow-up for women with no and non-obstructive disease respectively, with earlier time points not described[5]. Heart failure hospitalizations were also found in unexpectedly high incidence in the WISE cohort (11.2%), documented as the most common MACE following a diagnosis of CMD after being followed for 4.6-8.6 years[22]. These findings were after a duration of follow-up that has not yet been captured at our WHC.

After 3 years of follow-up in our WHC, a number of changes were observed in medical therapies. Short- and long-acting nitrates were common medications prescribed for both MINOCA and INOCA patients and are well-recognized for their antianginal properties[4,6]. Non-ASA antiplatelets were commonly deprescribed medications, which is supported by the lack of substantial benefit seen in the available literature[23]. The implementation of beta blockade in patients with MINOCA remains a nuanced decision, likely explaining why this therapy was both one of the greatest prescribed and deprescribed medications

over 3-years of follow-up. When Lindahl *et al.* assessed the utility of beta blockade, there was a trend towards a positive effect; however, the modality failed to reach significance[23]. This uncertain benefit is under further review, awaiting the results of the MINOCA-BAT trial[24]. Calcium channel blockers were one of the most prescribed medications for patients with INOCA, but not in MINOCA patients. This may be reflective of calcium channel blockers having been initiated in 42.6% of MINOCA patients prior to WHC enrolment, thus entering the WHC already on this appropriate therapy.

The 2023 JCS/CVIT/JCC guidelines on coronary vasospasm and CMD acknowledge that approximately 20% of patients may prove refractory to these therapies and warrant alternative therapeutic considerations[25]. Ranolazine is a piperazine derivative that selectively inhibits the late sodium current, with evidence suggestive of its benefit in coronary microcirculatory dysfunction; it can be considered as adjunctive therapy in chronic angina[26]. Ranolazine was one of the most prescribed medications for INOCA patients from enrolment to 3-years in the WHC, with 22% initiated on the therapy as compared to 4% of MINOCA patients.

Our study identified differences in angina through SAQ responses stratified by (M)INOCA group, depression status, and prescription of ranolazine at 3 years. INOCA patients experienced significant improvements across all SAQ subdomains. MINOCA patients did not observe a similar improvement in physical limitations; however, they

significantly improved in the other subdomains of angina frequency, quality of life, and treatment satisfaction.

Patients with depression at the time of WHC enrolment had significantly worse baseline SAQ scores across all metrics, including angina frequency and quality of life. Reassuringly, depression at baseline was not a significant modifier for any subdomain over 3 years, suggesting that patients with depression improved to a similar degree to those without depression. Mental health at presentation of cardiac symptoms has important implications for the interpretation of angina severity; a women's heart health psychiatrist is an important part of our team approach in the WHC and may help contribute to the favourable improvements seen in these patients. Acknowledging the bidirectional relationship between mental health and angina, attendance at a specialized clinic addressing both in unison also represents a plausible explanation for the improvements seen in these patients.

Improving mental health symptoms is not only an important priority for reducing symptom burden, but also reducing long-term cardiovascular outcomes. There is increasing appreciation of the interplay between mental health and cardiovascular health[27]. From a sex-specific perspective, not only are women twice as likely as men to be diagnosed with depression, the INTERHEART study found psychosocial factors increase the odds of MI by 3.5-fold in women as compared to 2.6-fold in men[28]. Further, depression was independently associated with post-MI angina in patients without obstructive CAD[9].

In this study, patients prescribed ranolazine by year 3 had significantly worse SAQ scores for all subdomains at the time of WHC enrolment. These patients subsequently improved by a similar degree across time points to patients not on ranolazine, except with regards to medication satisfaction, where ranolazine was a significant modifier towards greater improvement over time. This medication, which is new to Canada, is an important second line agent and should be considered early in treatment.

Limitations

WHCs are relatively novel entities, with our centre being one of 6 in Canada and the only center in British Columbia. As such, and by nature of our single-center data collection without a control group, this inherently brings with it limitations. Our patient population is predominantly Caucasian and other ethnicities are underrepresented. Further, due to referral of SCAD patients to a dedicated SCAD clinic rather than our WHC, this patient population is under-represented in this dataset compared to other studies of (M)INOCA patients. As such, the generalizability of our results to other WHCs with more representation of SCAD and other ethnicities is unclear. Lastly, it is unclear the extent to which our findings extend to male patients with nonobstructive vasomotor etiologies.

Conclusion

This study addresses a gap in longer-term data for (M)INOCA patients by presenting 3-year outcomes after specialized care in a Canadian WHC. The enhanced diagnostic clarity and the differentiation of symptom characteristics between these patient groups

underscore the importance of specialized continuity of care. These findings suggest that ongoing care through a WHC, including attention to mental health and tailored medication strategies, is crucial for achieving optimal outcomes in (M)INOCA patients. Further clinical trial and observational data to evaluate the efficacy of different medication regimens on MACE outcomes is warranted across larger cohorts representing more diverse gender and ethnic identities.

Acknowledgements

The authors would like to thank the patients attending the WHC for their participation in this research; statistician May Lee for her valuable consultation in statistical analysis; and Lily Cai, Andrew Starovoytov, Chenille Wong and Sasha Voznyuk in data collection.

The authors confirm that patient consent forms have been obtained for the WHC Registry through the University of British Columbia clinical research ethics board application #H13-03322. Secondary consent was not required for this article as aggregate deidentified data were used for the analyses as within scope of the WHC Registry protocol.

Funding sources

This work was supported through the 2022 BC Women's Hospital Women's Health Research Institute Catalyst Grant and support from the VGH Foundation.

Financial Disclosures

E.T. has received honorarium for speaking engagements from Amicus Therapeutics. T.S. has received honorarium for speaking engagements and advisory boards from KYE pharmaceuticals, Sanofi, Amgen, Pfizer, HLS pharmaceuticals, Novartis, BI-Lilly and Novo Nordisk. The other authors do not have any financial disclosures.

References

[1]Maddox TM, Stanislawski MA, Grunwald GK, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 2014;312:1754-63.

[2]Mahajan AM, Gandhi H, Smilowitz NR, et al. Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG. Int J Cardiol 2019;274:16-20.

[3]Theberge ET, Vikulova DN, Pimstone SN, et al. The Importance of Nontraditional and Sex-Specific Risk Factors in Young Women With Vasomotor Nonobstructive vs Obstructive Coronary Syndromes. CJC Open 2024;6:279-291.

[4]Agewall S, Beltrame JF, Reynolds HR, et al. WG on Cardiovascular Pharmacotherapy. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143-153.

[5]Sharaf B, Wood T, Shaw L, et al. Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. Am Heart J. 2013;166:134-141.

[6]Chaudhary, R, Bashline M, Novelli EM, et al. Sex-related differences in clinical outcomes among patients with myocardial infarction with nonobstructive coronary artery disease: a systematic review and meta-analysis. Int. J. Cardiol. 2022;369:1-4.

[7]Sedlak TL, Lee M, Izadnegahdar M, et al. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J. 2013;166(1):38-44.

[8]Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J. 2006;27(12):1408– 1415.

[9]Grodzinsky A, Arnold SV, Gosch K, et al. Angina Frequency After Acute Myocardial Infarction In Patients Without Obstructive Coronary Artery Disease. Eur Heart J Qual Care Clin Outcomes. 2015;1(2):92-99.

[10]Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol 2018;72(23 Pt A):2841-55.

[11]Parvand M, Ghadiri S, Théberge E, Comber L, Mullen KA, Bhalla NP, Johnson D, McKinley G, Sedlak TL. Sex, Gender, and Women's Heart Health: How Women's Heart Programs Address the Knowledge Gap. CJC Open. 2023;6(2Part B):442-453.

[12]Parvand M, Cai L, Ghadiri S, et al. One-year prospective follow-up of women with INOCA and MINOCA at a Canadian Women's Heart Centre. Can J Cardiol 2022;38:1600-10.

[13]Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.

[14]Bell RA, Franks P, Duberstein PR, et al. Suffering in silence: reasons for not disclosing depression in primary care. Ann Fam Med. 201;9(5):439-46.

[15]Glanville KP, Coleman JRI, Howard DM, et al. Multiple measures of depression to enhance validity of major depressive disorder in the UK Biobank. BJPsych Open. 2021;7(2):e44.

[16]Ong P, Camici PG, Beltrame JF, et al. Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16-20.

[17]Lioutas VA, Ivan CS, Himali JJ, et al. Incidence of Transient Ischemic Attack and Association With Long-term Risk of Stroke. JAMA. 2021;325(4):373-381.

[18]Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333-41.

[19]Guimarães WVN, Nicz PFG, Garcia-Garcia HM, et al. Seattle Angina Pectoris Questionnaire and Canadian Cardiovascular Society Angina Categories in the Assessment of Total Coronary Atherosclerotic Burden. Am J Cardiol. 2021;152:43-48.

[20]Hermesdorf M, Berger K, Baune BT, Wellmann J, Ruscheweyh R, Wersching H. Pain Sensitivity in Patients With Major Depression: Differential Effect of Pain Sensitivity Measures, Somatic Cofactors, and Disease Characteristics. J Pain. 2016;17(5):606-16.

[21]Shaw LJ, Merz CNB, Pepine CJ, et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. Circulation 2006;114:894-904.

[22]Bakir M, Nelson MD, Jones E, et al. Heart failure hospitalization in women with signs and symptoms of ischemia: A report from the women's ischemia syndrome evaluation study. Int J Cardiol. 2016;223:936-939.

[23]Lindahl, B. Baron T, Erlinge D, et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease. Circulation 2017;135, 1481-1489.

[24]Nordenskjold, A. M. Agewall S, Atar D, et al. Randomized evaluation of beta blocker and ACE-inhibitor/ angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): rationale and design. Am. Heart J. 2021;231:96–104.

[25]Hokimoto S, Kaikita K, Yasuda S, et al. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. J. Cardiol. 2023;82(4);293-341.

[26]Rayner-Hartley E, Sedlak T. Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016;5(3):e003196.

[27]Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation 2021;143:e763-83.

[28]Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.

Tables

Table 1: Baseline characteristics stratified by MINOCA and INOCA.

Variable		MINOCA (n=51)	INOCA (n=112)	p
Demographics				
Age, mean (s.d.)		55.7 (11.1)	58.3 (11.3)	0.16
Race, n Caucasian (%)		43 (84)	95 (85)	0.94
Partnered status, n partnered (%)		45 (88)	84 (75)	0.09
Education, n (%)	High school or less	7 (14)	20 (18)	0.76
	Some post-secondary	29 (57)	56 (50)	
	Higher than Bachelor's	9 (18)	25 (22)	
	*Missing**	*6 (12)*	*11 (10)*	
Working status, n (%)	Employed	31 (61)	56 (50)	0.36
	Not employed (including if retired)	15 (29)	46 (41)	
	On medical leave or disability	5 (10)	10 (9)	
Clinical				
Family history of premature heart disease, n (%)		12 (24)	39 (35)	0.21
Prior transient ischemic attack, n (%)		0 (0)	2 (2)	0.85
Dyslipidemia, n (%)		23 (45)	60 (54)	0.40
Diabetes, n (%)		9 (18)	13 (12)	0.42
Hypertension, n (%)		17 (33)	53 (47)	0.13
Obesity (Body mass index ≥30 kg/m^2), n (%)		4 (8)	24 (21)	0.06
Smoking history, n current or former (%)		9 (18)	22 (20)	0.93

Arrhythmia, n (%)		3 (6)	5 (4)	1
Depression, n (%)		19 (37)	52 (46)	0.36
Anxiety, n (%)		14 (27)	26 (23)	0.70
Thyroid dysfunction, n (%)		8 (16)	23 (21)	0.61
Chronic renal dysfunction, n (%)		1 (2)	2 (2)	1
Migraine history, n (%)		23 (45)	28 (25)	0.02
Raynaud's history, n (%)		7 (14)	9 (8)	0.40
Chronic obstructive pulmonary disease, n (%)		1 (2)	4 (4)	0.95
Autoimmune disease, n (%)		9 (18)	30 (27)	0.29
Female-specific				
Menopause status, n pre/peri (%)		15 (29)	30 (27)	0.87
Number of children born, n (%)	0 or 1	10 (20)	21 (19)	0.78
	2 or 3	31 (61)	72 (64)	
	4+	3 (6)	9 (8)	
	*Missing**	*7 (14)*	*10 (9)*	
Preeclampsia or hypertension in pregnancy, n (%)	Yes	10 (20)	16 (14)	0.39
	*Missing**	*7 (14)*	*10 (9)*	
Polycystic ovarian syndrome, n (%)	Yes	3 (6)	12 (11)	0.55
	*Missing**	*5 (10)*	*13 (12)*	

*Counts of missing variables included if over 5% were missing, and were not included in the p-value calculations.

Table 2: Comparing frequency of etiologies diagnosed following attendance at WHC.

Etiology	Total (n=163)	MINOCA (n=51)	INOCA (n=112)	p
Vasospasm	42 (26)	24 (47)	18 (16)	< 0.001
Definitive Vasospasm	*8 (5)*	*3 (6)*	*5 (4)*	-
Probable Vasospasm	*34 (21)*	*21 (41)*	*13 (12)*	-
CMD	92 (57)	7 (14)	85 (76)	< 0.001
Definite CMD	*14 (9)*	*2 (4)*	*12 (11)*	-
Probable CMD	*78 (48)*	*5 (10)*	*73 (65)*	-
Other non-vasomotor etiology	22 (13)	18 (35)	4 (4)	< 0.001
Not yet diagnosed	7 (4)	2 (4)	5 (4)	1

All values presented as n (%).

Table 3: Chest pain type frequency by MINOCA versus INOCA groups.

Chest pain component	MINOCA (n=51)	INOCA (n=112)	p
Combination of more than one chest pain type	34 (67)	66 (59)	<0.001
Exertional only	5 (10)	40 (36)	
Non-exertional only (at rest, sleep)	10 (20)	5 (4)	
With stress/emotional triggers only	2 (4)	1 (1)	

All values presented as n (%).

Table 4: Chest pain type frequency by CMD versus vasospasm diagnosis.

Chest pain component	CMD (n=92)	Vasospasm (n=42)	p
Exertional	80 (87)	19 (45)	< 0.001
Non-exertional (at rest, sleep)	34 (37)	28 (67)	0.003
With stress/emotional triggers	24 (26)	11 (26)	1

All values presented as n (%). Note chest pain totals do not add up to 100% for each diagnosis as some patients reported more than one type of chest pain.

Table 5: Comparing hospital encounters 3 years prior to baseline WHC appointment and 3 years following baseline.

Group	Encounter Type	Number of Encounters	Prior to WHC	Year 3	p
MINOCA (n=51)	ER Visits	0	4 (8)	25 (49)	< 0.001
		1 or 2	42 (82)	22 (43)	
		3+	5 (10)	4 (8)	
	Cardiovascular Hospitalizations	0	49 (96)	47 (92)	0.65
		1	2 (4)	3 (6)	
		2+	0 (0)	1 (2)	
INOCA (n=112)	ER Visits	0	56 (50)	74 (66)	0.03
		1 or 2	48 (43)	30 (27)	
		3+	8 (7)	8 (7)	
	Cardiovascular Hospitalizations	0	90 (80)	107 (96)	< 0.001
		1	20 (18)	4 (4)	
		2+	2 (2)	1 (1)	

All values represented as n (%).

Table 6: Major adverse cardiovascular event (MACE) outcomes after 3 years attendance at the WHC in (M)INOCA groups.

Group	MACE		Pre-WHC	Post-WHC
MINOCA (n=51)	**# MI**	**1**	46 (90)	1 (2)
		2	5 (10)	0
	TIA		0	1 (2)
	PCI		0	1 (2)
	Heart failure		0	0
	Death		0	0
INOCA (n=112)	**MI**		0	0
	TIA		2 (2)	2 (2)
	PCI		0	2 (2)
	Heart Failure		0	0
	Death		-	1 (1)

All values represented as n (%).

MI = Myocardial infarction, **TIA** = Transient ischemic attack, **PCI** = Percutaneous coronary intervention.

Table 7: Comparing SAQ subdomain questionnaire scores at baseline compared to 3 years.

Group	Questionnaire	Baseline	Year 3	p
MINOCA (n=51)	Physical Limitations	71 (56, 86)	71 (63, 79)	0.47
	Angina Frequency	60 (37, 84)	80 (56, 100)	0.03
	Quality of Life	50 (34, 67)	67 (55, 80)	< 0.001
	Treatment Satisfaction	76 (56, 97)	82 (70, 94)	< 0.01
INOCA (n=112)	Physical Limitations	51 (36, 66)	60 (45, 76)	< 0.001
	Angina Frequency	47 (31, 64)	67 (47, 87)	< 0.001
	Quality of Life	33 (17, 50)	47 (53, 82)	< 0.001
	Treatment Satisfaction	71 (59, 83)	82 (70, 94)	0.02

All values represented as median (interquartile range).

Figure Legends

Figure 1: Diagnoses of 163 patients studied before and 3 years after attendance at the WHC.

Figure 2. Proportions of therapies prescribed at WHC baseline and 3 years post-baseline in patients with A. MINOCA or B. INOCA.

ACE = Angiotensin-converting enzyme inhibitor, **ARB** = Angiotensin II receptor antagonist, **ASA** = Acetylsalicylic acid, **BB** = Beta blocker, **CCB** = Calcium channel blocker, **DHP** = 1,4-Dihydropyridine, **GLP-1** = Glucagon-like peptide-1, **HRT** = Hormone replacement therapy, **IDN** = Isosorbide dinitrate, **IMN** = Isosorbide mononitrate, **NSAID** = Non-steroidal anti-inflammatory drug, **PCSK9** = Proprotein convertase subtilisin/kexin type 9, **SGLT-2** = Sodium-glucose cotransporter-2

Figure 3. Changes in medications between WHC baseline and 3 years post-baseline for A. MINOCA and B. INOCA patients.

ACE = Angiotensin-converting enzyme inhibitor, **ARB** = Angiotensin II receptor antagonist, **ASA** = Acetylsalicylic acid, **BB** = Beta blocker, **CCB** = Calcium channel blocker, **DHP** = 1,4-Dihydropyridine, **GLP-1** = Glucagon-like peptide-1, **HRT** = Hormone replacement therapy, **IDN** = Isosorbide dinitrate, **IMN** = Isosorbide mononitrate, **NSAID** = Non-steroidal anti-inflammatory drug, **PCSK9** = Proprotein convertase subtilisin/kexin type 9, **SGLT-2** = Sodium-glucose cotransporter-2

Figure 4: Proportion of patients who had minimal clinically important differences (MCID) in domain scores between baseline and 3 years, stratified by (M)INOCA.

Figure 5. SAQ subdomain scores at baseline WHC appointment compared to 3 years later, by depression status at baseline, for: A. Physical limitations; B. Angina Frequency; C. Quality of Life; D. Treatment Satisfaction.

Figure 6. SAQ subdomain scores and standard deviation (SD) at baseline WHC appointment compared to 3 years later, by patients on ranolazine at year 3 compared to those not, for A. Physical limitations; B. Angina Frequency; C. Quality of Life; D. Treatment Satisfaction.


5%
6%
9%
80%
56%
26%
13%
4%
Diagnosis pre-WHC
Diagnosis post-WHC
Diagnosis
None
Other
Vasospasm
CMD


A.
Percent
60%
50%
40%
30%
20%
10%
0%
Timepoint
Baseline
Year 3
ASA
Statin
CCB - DHPs
BB
ACEi or ARB
Antidepressant
Long-acting nitrates
Short-acting nitrates
CCB - Non-DHPs
Antiglycemic - Other
HRT
Antiplatelet
Diuretic
Ezetimibe
Anticoagulant
Antiglycemic - GLP-1 agonists
Antiglycemic - Insulin
Antiglycemic - SGLT-2 inhibitors
Ivabradine
PCSK9 Inhibitor
Ranolazine
Spinal cord stimulator
Medications
B.
Percent
50%
40%
30%
20%
10%
0%
Timepoint
Baseline
Year 3
ASA
Statin
CCB - DHPs
BB
Antidepressant
Long-acting nitrates
ACEi or ARB
Short-acting nitrates
CCB - Non-DHPs
Diuretic
HRT
Antiglycemic - Other
Anticoagulant
Antiglycemic - Insulin
Antiplatelet
Antiglycemic - GLP-1 agonists
Ivabradine
Antiglycemic - SGLT-2 inhibitors
Ezetimibe
PCSK9 Inhibitor
Ranolazine
Spinal cord stimulator
Medications


A.
Prescribed
Stayed On
Deprescribed
Percent
50%
40%
30%
20%
10%
0%
Long-acting nitrates
Short-acting nitrates
BB
ASA
CCB - DHPs
Statin
CCB - Non-DHPs
ACEi or ARB
Diuretic
Antidepressant
Ivabradine
Ranolazine
Anticoagulant
Antiplatelet
HRT
Spinal cord stimulator
Antiglycemic - GLP-1 agonists
Antiglycemic - Insulin
Antiglycemic - Other
Antiglycemic - SGLT-2 inhibitors
Ezetimibe
PCSK9 Inhibitor
Medications
B.
Prescribed
Stayed On
Deprescribed
Percent
30%
20%
10%
0%
Long-acting nitrates
CCB - DHPs
Short-acting nitrates
Ranolazine
BB
Statin
ASA
CCB - Non-DHPs
ACEi or ARB
Diuretic
Ezetimibe
Antidepressant
PCSK9 Inhibitor
Antiglycemic - Other
Anticoagulant
Antiplatelet
HRT
Ivabradine
Antiglycemic - Insulin
Antiglycemic - SGLT-2 inhibitors
Spinal cord stimulator
Antiglycemic - GLP-1 agonists
Medications


MINOCA
INOCA
100%
75%
50%
25%
0%
Percent
SAQ Angina Frequency
SAQ Physical Limitations
SAQ Quality of Life
SAQ Treatment Satisfaction
SAQ Angina Frequency
SAQ Physical Limitations
SAQ Quality of Life
SAQ Treatment Satisfaction
SAQ Subdomain
Category
Worsened
No change
Improved


A.
B.
C.
D.
Score
100
75
50
25
0
Baseline
Year 3
Timepoint
Depression at baseline?
No
Yes


A.
B.
C.
D.
Score
100
75
50
25
0
Baseline
Year 3
Timepoint
On Ranolazine at 3 years?
No
Yes